Use of Enzymatically Activated Carbon Monoxide Donors for Sensitizing Drug-Resistant Tumor Cells

Int J Mol Sci. 2023 Jul 9;24(14):11258. doi: 10.3390/ijms241411258.

Abstract

The application of gaseous signaling molecules like NO, H2S or CO to overcome the multidrug resistance in cancer treatment has proven to be a viable therapeutic strategy. The development of CO-releasing molecules (CORMs) in a controlled manner and in targeted tissues remains a challenge in medicinal chemistry. In this paper, we describe the design, synthesis and chemical and enzymatic stability of a novel non-metal CORM (1) able to release intracellularly CO and, simultaneously, facilitate fluorescent degradation of products under the action of esterase. The toxicity of 1 against different human cancer cell lines and their drug-resistant counterparts, as well as the putative mechanism of toxicity were investigated. The drug-resistant cancer cell lines efficiently absorbed 1 and 1 was able to restore their sensitivity vs. chemotherapeutic drugs by causing a CO-dependent mitochondrial oxidative stress that culminated in mitochondrial-dependent apoptosis. These results demonstrate the importance of CORMs in cases where conventional chemotherapy fails and thus open the horizons towards new combinatorial strategies to overcome multidrug resistance.

Keywords: antitumor activity; carbon monoxide; carbon monoxide releasing molecules (CORMs); mitochondrial damage; multidrug resistance.

MeSH terms

  • Apoptosis
  • Carbon Monoxide* / chemistry
  • Carbon Monoxide* / pharmacology
  • Charcoal
  • Humans
  • Mitochondria / metabolism
  • Organometallic Compounds* / chemistry
  • Organometallic Compounds* / pharmacology
  • Signal Transduction

Substances

  • Carbon Monoxide
  • Charcoal
  • Organometallic Compounds